Asensus Surgical, Inc. Logo

Asensus Surgical, Inc.

ASXC

(1.2)
Stock Price

0,35 USD

-223.52% ROA

-406.97% ROE

-1.13x PER

Market Cap.

94.922.082,00 USD

-180.39% DER

0% Yield

-850.75% NPM

Asensus Surgical, Inc. Stock Analysis

Asensus Surgical, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Asensus Surgical, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.92x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (9%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

4 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

5 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

6 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

7 ROE

Negative ROE (-90.09%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

8 ROA

The stock's ROA (-103.55%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

9 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

10 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

11 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Asensus Surgical, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Asensus Surgical, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Asensus Surgical, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Asensus Surgical, Inc. Revenue
Year Revenue Growth
1990 1.400.000
1991 2.300.000 39.13%
1992 4.800.000 52.08%
1993 5.300.000 9.43%
1994 9.700.000 45.36%
1995 12.100.000 19.83%
1996 20.900.000 42.11%
1997 30.300.000 31.02%
1998 12.000.000 -152.5%
1999 10.200.000 -17.65%
2000 25.973.000 60.73%
2001 20.416.000 -27.22%
2002 11.771.000 -73.44%
2003 231.000 -4995.67%
2004 0 0%
2005 0 0%
2006 0 0%
2007 -135.000 100%
2008 0 0%
2009 0 0%
2010 -29 100%
2011 0 0%
2012 35.000 100%
2013 1.431.000 97.55%
2014 401.000 -256.86%
2015 0 0%
2016 1.519.000 100%
2017 7.111.000 78.64%
2018 24.102.000 70.5%
2019 8.531.000 -182.52%
2020 3.175.000 -168.69%
2021 8.232.000 61.43%
2022 7.087.000 -16.16%
2023 4.356.000 -62.7%
2023 8.577.000 49.21%
2024 8.828.000 2.84%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Asensus Surgical, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1990 0
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 3.500.000 100%
1996 5.500.000 36.36%
1997 8.100.000 32.1%
1998 4.500.000 -80%
1999 1.600.000 -181.25%
2000 1.480.000 -8.11%
2001 1.841.000 19.61%
2002 1.522.000 -20.96%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1.636.000 100%
2008 2.682.000 39%
2009 1.256.000 -113.54%
2010 2.728.000 53.96%
2011 3.367.000 18.98%
2012 2.916.000 -15.47%
2013 12.700.000 77.04%
2014 27.944.000 54.55%
2015 29.669.000 5.81%
2016 29.273.000 -1.35%
2017 21.989.000 -33.13%
2018 21.823.000 -0.76%
2019 22.468.000 2.87%
2020 16.621.000 -35.18%
2021 19.348.000 14.09%
2022 28.942.000 33.15%
2023 37.160.000 22.12%
2023 37.023.000 -0.37%
2024 30.524.000 -21.29%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Asensus Surgical, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1990 0
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 2.763.000 100%
2013 4.221.000 34.54%
2014 6.244.000 32.4%
2015 7.831.000 20.27%
2016 10.813.000 27.58%
2017 12.275.000 11.91%
2018 13.854.000 11.4%
2019 18.758.000 26.14%
2020 14.137.000 -32.69%
2021 19.323.000 26.84%
2022 20.172.000 4.21%
2023 18.284.000 -10.33%
2023 19.155.000 4.55%
2024 23.976.000 20.11%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Asensus Surgical, Inc. EBITDA
Year EBITDA Growth
1990 -1.200.000
1991 -1.200.000 0%
1992 -1.000.000 -20%
1993 -200.000 -400%
1994 2.000.000 110%
1995 700.000 -185.71%
1996 -6.000.000 111.67%
1997 -2.200.000 -172.73%
1998 -5.100.000 56.86%
1999 3.000.000 270%
2000 -450.000 766.67%
2001 -1.082.000 58.41%
2002 -1.614.000 32.96%
2003 -986.000 -63.69%
2004 -473.000 -108.46%
2005 -318.000 -48.74%
2006 -372.000 14.52%
2007 -2.484.000 85.02%
2008 -5.106.000 51.35%
2009 -2.599.000 -96.46%
2010 -5.298.000 50.94%
2011 -5.533.000 4.25%
2012 -6.502.000 14.9%
2013 -17.082.000 61.94%
2014 -35.299.000 51.61%
2015 -35.276.000 -0.07%
2016 21.050.000 267.58%
2017 36.830.000 42.85%
2018 -48.536.000 175.88%
2019 -79.659.000 39.07%
2020 -42.999.000 -85.26%
2021 -50.187.000 14.32%
2022 -63.441.000 20.89%
2023 -79.116.000 19.81%
2023 -74.401.000 -6.34%
2024 -67.564.000 -10.12%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Asensus Surgical, Inc. Gross Profit
Year Gross Profit Growth
1990 -1.200.000
1991 1.500.000 180%
1992 2.700.000 44.44%
1993 3.400.000 20.59%
1994 7.000.000 51.43%
1995 8.900.000 21.35%
1996 6.200.000 -43.55%
1997 14.300.000 56.64%
1998 2.500.000 -472%
1999 7.700.000 67.53%
2000 5.441.000 -41.52%
2001 4.317.000 -26.04%
2002 220.000 -1862.27%
2003 49.000 -348.98%
2004 0 0%
2005 0 0%
2006 0 0%
2007 -135.000 100%
2008 0 0%
2009 0 0%
2010 -29 100%
2011 0 0%
2012 -347.000 100%
2013 -3.379.000 89.73%
2014 -694.000 -386.89%
2015 -2.185.000 68.24%
2016 450.000 585.56%
2017 384.000 -17.19%
2018 7.931.000 95.16%
2019 -12.200.000 165.01%
2020 -1.991.000 -512.76%
2021 -2.864.000 30.48%
2022 -3.785.000 24.33%
2023 -7.120.000 46.84%
2023 -5.031.000 -41.52%
2024 -2.248.000 -123.8%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Asensus Surgical, Inc. Net Profit
Year Net Profit Growth
1990 -1.600.000
1991 -1.000.000 -60%
1992 -1.500.000 33.33%
1993 -1.200.000 -25%
1994 1.500.000 180%
1995 100.000 -1400%
1996 -7.400.000 101.35%
1997 -5.000.000 -48%
1998 -10.900.000 54.13%
1999 2.600.000 519.23%
2000 2.552.000 -1.88%
2001 611.000 -317.68%
2002 -5.476.000 111.16%
2003 -967.000 -466.29%
2004 -444.000 -117.79%
2005 -228.000 -94.74%
2006 -204.000 -11.76%
2007 -3.041.000 93.29%
2008 -5.185.000 41.35%
2009 -2.366.000 -119.15%
2010 -5.303.000 55.38%
2011 -5.758.000 7.9%
2012 -6.724.000 14.37%
2013 -28.358.000 76.29%
2014 -37.652.000 24.68%
2015 -46.948.000 19.8%
2016 -119.980.000 60.87%
2017 -144.796.000 17.14%
2018 -61.777.000 -134.38%
2019 -154.201.000 59.94%
2020 -59.312.000 -159.98%
2021 -62.462.000 5.04%
2022 -75.561.000 17.34%
2023 -73.272.000 -3.12%
2023 -78.433.000 6.58%
2024 -102.996.000 23.85%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Asensus Surgical, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1990 -7
1991 -52 88.24%
1992 -5 -920%
1993 -4 -66.67%
1994 4 175%
1995 0 0%
1996 -17 100%
1997 -11 -45.45%
1998 -24 52.17%
1999 6 560%
2000 6 0%
2001 1 -400%
2002 -12 109.09%
2003 -2 -450%
2004 -1 0%
2005 0 0%
2006 0 0%
2007 -1 100%
2008 -2 0%
2009 -1 0%
2010 -1 100%
2011 -1 0%
2012 -6 83.33%
2013 -2 -200%
2014 -1 0%
2015 -1 0%
2016 -1 100%
2017 -1 0%
2018 -4 100%
2019 -9 62.5%
2020 -1 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Asensus Surgical, Inc. Free Cashflow
Year Free Cashflow Growth
1991 -1.000.000
1992 -1.800.000 44.44%
1993 -1.300.000 -38.46%
1994 2.500.000 152%
1995 -800.000 412.5%
1996 -12.000.000 93.33%
1997 -400.000 -2900%
1998 -1.600.000 75%
1999 4.200.000 138.1%
2000 342.000 -1128.07%
2001 1.807.000 81.07%
2002 -3.041.000 159.42%
2003 -704.000 -331.96%
2004 -452.000 -55.75%
2005 -219.000 -106.39%
2006 -27.000 -711.11%
2007 -3.146.000 99.14%
2008 -4.058.000 22.47%
2009 -2.625.000 -54.59%
2010 -4.810.000 45.43%
2011 -5.160.000 6.78%
2012 -6.968.000 25.95%
2013 -22.613.000 69.19%
2014 -35.402.000 36.13%
2015 -39.743.000 10.92%
2016 -53.747.000 26.06%
2017 -41.786.000 -28.62%
2018 -49.263.000 15.18%
2019 -73.921.000 33.36%
2020 -46.678.000 -58.36%
2021 -42.027.000 -11.07%
2022 -60.216.000 30.21%
2023 -64.188.000 6.19%
2023 -15.371.000 -317.59%
2024 -14.331.000 -7.26%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Asensus Surgical, Inc. Operating Cashflow
Year Operating Cashflow Growth
1991 -700.000
1992 -1.200.000 41.67%
1993 -900.000 -33.33%
1994 3.200.000 128.13%
1995 800.000 -300%
1996 -10.300.000 107.77%
1997 1.600.000 743.75%
1998 -1.400.000 214.29%
1999 4.200.000 133.33%
2000 1.026.000 -309.36%
2001 1.879.000 45.4%
2002 -3.030.000 162.01%
2003 -704.000 -330.4%
2004 -452.000 -55.75%
2005 -219.000 -106.39%
2006 -27.000 -711.11%
2007 -2.946.000 99.08%
2008 -4.031.000 26.92%
2009 -2.590.000 -55.64%
2010 -4.533.000 42.86%
2011 -4.867.000 6.86%
2012 -6.939.000 29.86%
2013 -21.236.000 67.32%
2014 -33.228.000 36.09%
2015 -38.509.000 13.71%
2016 -52.386.000 26.49%
2017 -39.795.000 -31.64%
2018 -48.493.000 17.94%
2019 -73.484.000 34.01%
2020 -46.675.000 -57.44%
2021 -40.659.000 -14.8%
2022 -58.937.000 31.01%
2023 -63.627.000 7.37%
2023 -15.049.000 -322.8%
2024 -14.220.000 -5.83%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Asensus Surgical, Inc. Capital Expenditure
Year Capital Expenditure Growth
1991 300.000
1992 600.000 50%
1993 400.000 -50%
1994 700.000 42.86%
1995 1.600.000 56.25%
1996 1.700.000 5.88%
1997 2.000.000 15%
1998 200.000 -900%
1999 0 0%
2000 684.000 100%
2001 72.000 -850%
2002 11.000 -554.55%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 200.000 100%
2008 27.000 -640.74%
2009 35.000 22.86%
2010 277.000 87.36%
2011 293.000 5.46%
2012 29.000 -910.34%
2013 1.377.000 97.89%
2014 2.174.000 36.66%
2015 1.234.000 -76.18%
2016 1.361.000 9.33%
2017 1.991.000 31.64%
2018 770.000 -158.57%
2019 437.000 -76.2%
2020 3.000 -14466.67%
2021 1.368.000 99.78%
2022 1.279.000 -6.96%
2023 561.000 -127.99%
2023 322.000 -74.22%
2024 111.000 -190.09%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Asensus Surgical, Inc. Equity
Year Equity Growth
1990 -300.000
1991 5.600.000 105.36%
1992 9.500.000 41.05%
1993 9.100.000 -4.4%
1994 13.700.000 33.58%
1995 16.700.000 17.96%
1996 18.200.000 8.24%
1997 13.900.000 -30.94%
1998 3.100.000 -348.39%
1999 5.700.000 45.61%
2000 8.268.000 31.06%
2001 8.879.000 6.88%
2002 3.403.000 -160.92%
2003 2.505.000 -35.85%
2004 2.113.000 -18.55%
2005 3.472.000 39.14%
2006 3.270.000 -6.18%
2007 2.421.000 -35.07%
2008 1.473.000 -64.36%
2009 1.284.000 -14.72%
2010 3.424.000 62.5%
2011 -1.999.000 271.29%
2012 245.000 915.92%
2013 105.023.000 99.77%
2014 121.789.000 13.77%
2015 177.277.000 31.3%
2016 117.870.000 -50.4%
2017 178.848.000 34.09%
2018 168.521.000 -6.13%
2019 55.535.000 -203.45%
2020 61.569.000 9.8%
2021 169.246.000 63.62%
2022 99.645.000 -69.85%
2023 33.414.000 -198.21%
2023 47.253.000 29.29%
2024 -11.327.000 517.17%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Asensus Surgical, Inc. Assets
Year Assets Growth
1990 2.100.000
1991 6.600.000 68.18%
1992 10.100.000 34.65%
1993 9.900.000 -2.02%
1994 15.500.000 36.13%
1995 18.400.000 15.76%
1996 32.400.000 43.21%
1997 20.700.000 -56.52%
1998 8.100.000 -155.56%
1999 10.200.000 20.59%
2000 9.774.000 -4.36%
2001 9.990.000 2.16%
2002 4.144.000 -141.07%
2003 2.681.000 -54.57%
2004 2.199.000 -21.92%
2005 3.555.000 38.14%
2006 3.528.000 -0.77%
2007 2.684.000 -31.45%
2008 1.746.000 -53.72%
2009 1.427.000 -22.35%
2010 3.694.000 61.37%
2011 993.000 -272%
2012 2.420.000 58.97%
2013 116.714.000 97.93%
2014 135.211.000 13.68%
2015 248.602.000 45.61%
2016 176.249.000 -41.05%
2017 250.251.000 29.57%
2018 239.307.000 -4.57%
2019 74.779.000 -220.02%
2020 78.258.000 4.45%
2021 186.473.000 58.03%
2022 116.053.000 -60.68%
2023 60.534.000 -91.72%
2023 70.727.000 14.41%
2024 38.502.000 -83.7%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Asensus Surgical, Inc. Liabilities
Year Liabilities Growth
1990 2.100.000
1991 1.000.000 -110%
1992 600.000 -66.67%
1993 800.000 25%
1994 1.800.000 55.56%
1995 1.700.000 -5.88%
1996 14.200.000 88.03%
1997 6.800.000 -108.82%
1998 5.000.000 -36%
1999 4.500.000 -11.11%
2000 1.506.000 -198.8%
2001 1.111.000 -35.55%
2002 741.000 -49.93%
2003 176.000 -321.02%
2004 86.000 -104.65%
2005 83.000 -3.61%
2006 258.000 67.83%
2007 263.000 1.9%
2008 273.000 3.66%
2009 143.000 -90.91%
2010 270.000 47.04%
2011 2.992.000 90.98%
2012 2.175.000 -37.56%
2013 11.691.000 81.4%
2014 13.422.000 12.9%
2015 71.325.000 81.18%
2016 58.379.000 -22.18%
2017 71.403.000 18.24%
2018 70.786.000 -0.87%
2019 19.244.000 -267.83%
2020 16.689.000 -15.31%
2021 17.227.000 3.12%
2022 16.408.000 -4.99%
2023 27.120.000 39.5%
2023 23.474.000 -15.53%
2024 49.829.000 52.89%

Asensus Surgical, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.04
Net Income per Share
-0.31
Price to Earning Ratio
-1.13x
Price To Sales Ratio
9.64x
POCF Ratio
-1.67
PFCF Ratio
-1.66
Price to Book Ratio
-8.36
EV to Sales
10.92
EV Over EBITDA
-1.58
EV to Operating CashFlow
-1.9
EV to FreeCashFlow
-1.88
Earnings Yield
-0.88
FreeCashFlow Yield
-0.6
Market Cap
0,09 Bil.
Enterprise Value
0,11 Bil.
Graham Number
0.54
Graham NetNet
-0.14

Income Statement Metrics

Net Income per Share
-0.31
Income Quality
0.68
ROE
-4.07
Return On Assets
-2.18
Return On Capital Employed
50.15
Net Income per EBT
1
EBT Per Ebit
1.17
Ebit per Revenue
-7.22
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
1.92
Research & Developement to Revenue
3.41
Stock Based Compensation to Revenue
0.59
Gross Profit Margin
-0.34
Operating Profit Margin
-7.22
Pretax Profit Margin
-8.47
Net Profit Margin
-8.51

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.21
Free CashFlow per Share
-0.21
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.05
Capex to Depreciation
0.13
Return on Invested Capital
-7.84
Return on Tangible Assets
-2.24
Days Sales Outstanding
15.04
Days Payables Outstanding
56.94
Days of Inventory on Hand
198.2
Receivables Turnover
24.26
Payables Turnover
6.41
Inventory Turnover
1.84
Capex per Share
0

Balance Sheet

Cash per Share
0,03
Book Value per Share
-0,04
Tangible Book Value per Share
-0.04
Shareholders Equity per Share
-0.04
Interest Debt per Share
0.07
Debt to Equity
-1.8
Debt to Assets
0.53
Net Debt to EBITDA
-0.19
Current Ratio
0.49
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,03 Bil.
Invested Capital
-6745000
Working Capital
-0,02 Bil.
Intangibles to Total Assets
0.03
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
6559000
Debt to Market Cap
0.22

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Asensus Surgical, Inc. Dividends
Year Dividends Growth

Asensus Surgical, Inc. Profile

About Asensus Surgical, Inc.

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

CEO
Mr. Anthony Fernando
Employee
207
Address
1 TW Alexander Drive
Durham, 27703

Asensus Surgical, Inc. Executives & BODs

Asensus Surgical, Inc. Executives & BODs
# Name Age
1 Mr. Ethan Loiselle
Vice President of Global Marketing
70
2 Mr. Motti Frimer
Vice President of R&D, Digital Solutions and MD of Asensus Surgical
70
3 Mr. Anthony Fernando
President, Chief Executive Officer & Director
70
4 Mr. Joshua B. Weingard
Chief Legal Officer & Secretary
70
5 Mr. Shameze Rampertab B.Sc. MBA, CA, CPA
Executive Vice President & Chief Financial Officer
70
6 Mr. Ravi Kommineni
Head of Global Quality & Regulatory
70

Asensus Surgical, Inc. Competitors